Clinical trial

JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC

NCT07714304

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-07-13

PhaseNA

Study timeline

Study start (estimated)2026-07-13Date precision: day

Registry last updated2026-07-20

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

NSCLC Harboring EGFR Mutationsunresolved

Interventions

JS212 for InjectionDRUG

JS111 capsules (AP-L1898)DRUG

Sponsors & collaborators

Huan Zhoulead sponsor

Mapped research locations

ShanghaiShanghai Municipality, China1 HefeiAnhui, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07714304 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.